Clinicopathologic Characteristics and Long-Term Prognosis of Scirrhous Hepatocellular Carcinoma

被引:36
作者
Lee, Jin Hee [1 ]
Choi, Moon Seok [1 ]
Gwak, Geum Yeon [1 ]
Lee, Joon Hyeok [1 ]
Koh, Kwang Cheol [1 ]
Paik, Seung Woon [1 ]
Yoo, Byung Chul [1 ]
Choi, Dongil [2 ,3 ]
Park, Cheol Keun [4 ]
机构
[1] Sungkyunkwan Univ, Sch Med, Samsung Med Ctr, Dept Med, Seoul 135710, South Korea
[2] Sungkyunkwan Univ, Sch Med, Samsung Med Ctr, Dept Radiol, Seoul 135710, South Korea
[3] Sungkyunkwan Univ, Sch Med, Samsung Med Ctr, Ctr Imaging Sci, Seoul 135710, South Korea
[4] Sungkyunkwan Univ, Sch Med, Samsung Med Ctr, Dept Pathol, Seoul 135710, South Korea
关键词
Scirrhous hepatocellular carcinoma; Hepatectomy; Prognosis; Survival; Recurrence; HEPATIC STELLATE CELLS; CHOLANGIOCARCINOMA; FEATURES; ANGIOGENESIS; ENHANCEMENT; EXPRESSION; HYPOXIA;
D O I
10.1007/s10620-012-2075-x
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Clinicopathologic features and long-term outcomes in patients with scirrhous hepatocellular carcinoma (S-HCC) are not fully defined. We compared data of 37 patients with S-HCC and 604 with usual HCC (U-HCC) undergoing surgery. The S-HCC group showed less HBV infection (78.4 vs. 92.0%, P = 0.02), low serum AFP level (2320 +/- A 6356 vs. 3297 +/- A 18690 ng/ml, P < 0.0001), less delayed washout during CT (72.7 vs. 90.7%, P = 0.004), and low usefulness of clinical diagnostic criteria (32.4 vs. 57.5%, P = 0.003), compared to the U-HCC group. More portal vein invasion (18.9 vs. 4.1%, P = 0.03) and less liver cirrhosis (35.1 vs. 65.1%, P = 0.001) and fibrous capsule (40.5 vs. 81.6%, P < 0.001) were noted in the S-HCC group than the U-HCC group. Long-term survival rates were similar between the S-HCC and U-HCC groups, even with subgroup analysis according to Child-Pugh score and modified UICC stage. The S-HCC group showed distinct patient and tumor characteristics but similar long-term outcome.
引用
收藏
页码:1698 / 1707
页数:10
相关论文
共 28 条
[1]  
[Anonymous], 1997, J CLIN PATHOL
[2]   Delayed-phase dynamic CT enhancement as a prognostic factor for mass-forming intrahepatic cholangiocarcinoma [J].
Asayama, Y ;
Yoshimitsu, K ;
Irie, H ;
Tajima, T ;
Nishie, A ;
Hirakawa, M ;
Nakayama, T ;
Kakihara, D ;
Taketomi, A ;
Aishima, S ;
Honda, H .
RADIOLOGY, 2006, 238 (01) :150-155
[3]   Management of hepatoceullular carcinoma [J].
Bruix, J ;
Sherman, M .
HEPATOLOGY, 2005, 42 (05) :1208-1236
[4]   Clinical management of hepatocellular carcinoma.: Conclusions of the Barcelona-2000 EASL Conference [J].
Bruix, J ;
Sherman, M ;
Llovet, JM ;
Beaugrand, M ;
Lencioni, R ;
Burroughs, AK ;
Christensen, E ;
Pagliaro, L ;
Colombo, M ;
Rodés, J .
JOURNAL OF HEPATOLOGY, 2001, 35 (03) :421-430
[5]   Prognostic models including the Child-Pugh, MELD and Mayo risk scores - where are we and where should we go? [J].
Christensen, E .
JOURNAL OF HEPATOLOGY, 2004, 41 (02) :344-350
[6]   Hepatocyte antigen as a marker of hepatocellular carcinoma - An immunohistochemical comparison to carcinoembryonic antigen, CD10, and alpha-fetoprotein [J].
Chu, PGG ;
Ishizawa, S ;
Wu, E ;
Weiss, LM .
AMERICAN JOURNAL OF SURGICAL PATHOLOGY, 2002, 26 (08) :978-988
[7]   Hypoxia-inducible factor-1α regulates the expression of genes in hypoxic hepatic stellate cells important for collagen deposition and angiogenesis [J].
Copple, Bryan L. ;
Bai, Shan ;
Burgoon, Lyle D. ;
Moon, Jeon-OK .
LIVER INTERNATIONAL, 2011, 31 (02) :230-244
[8]   Small scirrhous hepatocellular carcinoma with central scar: MR imaging findings [J].
Goshima, S ;
Kanematsu, M ;
Yamada, T ;
Kondo, H ;
Matsuo, M ;
Osada, S ;
Nakashima, O ;
Moriyama, N ;
Hoshi, H .
JOURNAL OF MAGNETIC RESONANCE IMAGING, 2002, 16 (06) :741-745
[9]  
IHA H, 1994, ACTA HEPATOL JPN, V28, P855, DOI DOI 10.2957/KANZO.35.855
[10]   Report of the 15th follow-up survey of primary liver cancer [J].
Ikai, I ;
Itai, Y ;
Okita, K ;
Omata, M ;
Kojiro, M ;
Kobayashi, K ;
Nakanuma, Y ;
Futagawa, S ;
Makuuchi, M ;
Yamaoka, Y .
HEPATOLOGY RESEARCH, 2004, 28 (01) :21-29